David B. Rawlins

1.5k total citations
17 papers, 614 citations indexed

About

David B. Rawlins is a scholar working on Oncology, Organic Chemistry and Molecular Biology. According to data from OpenAlex, David B. Rawlins has authored 17 papers receiving a total of 614 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 6 papers in Organic Chemistry and 6 papers in Molecular Biology. Recurrent topics in David B. Rawlins's work include Diabetes Treatment and Management (5 papers), Pancreatic function and diabetes (5 papers) and Cancer Treatment and Pharmacology (4 papers). David B. Rawlins is often cited by papers focused on Diabetes Treatment and Management (5 papers), Pancreatic function and diabetes (5 papers) and Cancer Treatment and Pharmacology (4 papers). David B. Rawlins collaborates with scholars based in United States, Japan and Germany. David B. Rawlins's co-authors include Nicole C. Goodwin, Bryce A. Harrison, Faika Mseeh, Paul A. Wender, Alan Wilson, David R. Powell, Ross Mabon, Melanie K. Shadoan, S. David Kimball and Brian Zambrowicz and has published in prestigious journals such as Journal of Medicinal Chemistry, Journal of Pharmacology and Experimental Therapeutics and The Journal of Organic Chemistry.

In The Last Decade

David B. Rawlins

17 papers receiving 592 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David B. Rawlins United States 11 269 231 199 178 94 17 614
Takashi Santou Japan 12 297 1.1× 437 1.9× 132 0.7× 188 1.1× 121 1.3× 12 682
Toshiaki Sakamoto Japan 13 215 0.8× 331 1.4× 306 1.5× 130 0.7× 90 1.0× 29 701
Monica Einstein United States 10 410 1.5× 432 1.9× 88 0.4× 109 0.6× 35 0.4× 14 826
Denise Blum‐Kaelin Switzerland 9 145 0.5× 173 0.7× 65 0.3× 222 1.2× 61 0.6× 11 445
Dirk Leysen Belgium 13 103 0.4× 259 1.1× 97 0.5× 57 0.3× 60 0.6× 27 647
Yoshimitsu Komatsu Japan 9 182 0.7× 150 0.6× 122 0.6× 97 0.5× 56 0.6× 17 462
Delvin R. Knight United States 17 121 0.4× 290 1.3× 139 0.7× 171 1.0× 50 0.5× 23 810
Changyou Zhou United States 15 107 0.4× 300 1.3× 179 0.9× 98 0.6× 106 1.1× 25 505
Guiqing Liang United States 11 122 0.5× 171 0.7× 104 0.5× 52 0.3× 55 0.6× 21 484
George Chiu United States 12 175 0.7× 273 1.2× 377 1.9× 64 0.4× 44 0.5× 42 903

Countries citing papers authored by David B. Rawlins

Since Specialization
Citations

This map shows the geographic impact of David B. Rawlins's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David B. Rawlins with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David B. Rawlins more than expected).

Fields of papers citing papers by David B. Rawlins

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David B. Rawlins. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David B. Rawlins. The network helps show where David B. Rawlins may publish in the future.

Co-authorship network of co-authors of David B. Rawlins

This figure shows the co-authorship network connecting the top 25 collaborators of David B. Rawlins. A scholar is included among the top collaborators of David B. Rawlins based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David B. Rawlins. David B. Rawlins is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Yellepeddi, Venkata, et al.. (2018). Biopharmaceutical Characterization and Oral Efficacy of a New Rapid Acting Antidepressant Ro 25-6981. Journal of Pharmaceutical Sciences. 107(9). 2472–2478. 9 indexed citations
2.
Powell, David R., Melinda Smith, Deon Doree, et al.. (2017). LX2761, a Sodium/Glucose Cotransporter 1 Inhibitor Restricted to the Intestine, Improves Glycemic Control in Mice. Journal of Pharmacology and Experimental Therapeutics. 362(1). 85–97. 25 indexed citations
3.
Goodwin, Nicole C., Zhi‐Ming Ding, Bryce A. Harrison, et al.. (2017). Discovery of LX2761, a Sodium-Dependent Glucose Cotransporter 1 (SGLT1) Inhibitor Restricted to the Intestinal Lumen, for the Treatment of Diabetes. Journal of Medicinal Chemistry. 60(2). 710–721. 57 indexed citations
4.
Powell, David R., Melinda Smith, Deon Doree, et al.. (2015). LP‐925219 maximizes urinary glucose excretion in mice by inhibiting both renal SGLT1 and SGLT2. Pharmacology Research & Perspectives. 3(2). e00129–e00129. 10 indexed citations
5.
Jessop, Theodore C., et al.. (2014). Reaction profiling by ultra high-pressure liquid chromatography/time-of-flight mass spectrometry in support of the synthesis of DNA-encoded libraries. Journal of Chromatography B. 971. 120–125. 4 indexed citations
6.
Goodwin, Nicole C., Giovanni Cianchetta, Ross Mabon, et al.. (2014). Discovery of a Type III Inhibitor of LIM Kinase 2 That Binds in a DFG-Out Conformation. ACS Medicinal Chemistry Letters. 6(1). 53–57. 48 indexed citations
7.
Zambrowicz, Brian, J Freiman, Phil Brown, et al.. (2012). LX4211, a Dual SGLT1/SGLT2 Inhibitor, Improved Glycemic Control in Patients With Type 2 Diabetes in a Randomized, Placebo-Controlled Trial. Clinical Pharmacology & Therapeutics. 92(2). 158–169. 202 indexed citations
8.
Goodwin, Nicole C., Ross Mabon, Bryce A. Harrison, et al.. (2009). Novel l-Xylose Derivatives as Selective Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitors for the Treatment of Type 2 Diabetes. Journal of Medicinal Chemistry. 52(20). 6201–6204. 63 indexed citations
9.
Misra, Raj N., David B. Rawlins, Hai-yun Xiao, et al.. (2003). 1H-Pyrazolo[3,4-b]pyridine Inhibitors of Cyclin-Dependent Kinases. Bioorganic & Medicinal Chemistry Letters. 13(6). 1133–1136. 55 indexed citations
10.
Misra, Raj N., Hai-yun Xiao, David B. Rawlins, et al.. (2003). 1H-Pyrazolo[3,4-b]pyridine inhibitors of cyclin-dependent kinases: highly potent 2,6-Difluorophenacyl analogues. Bioorganic & Medicinal Chemistry Letters. 13(14). 2405–2408. 63 indexed citations
11.
Misra, Raj N., Hai‐Yun Xiao, David B. Rawlins, et al.. (2003). 1H‐Pyrazolo[3,4‐b]pyridine Inhibitors of Cyclin‐Dependent Kinases: Highly Potent 2,6‐Difluorophenacyl Analogues.. ChemInform. 34(42). 1 indexed citations
12.
Wender, Paul A., et al.. (1996). The Pinene Path to Taxanes. 4. Approaches to Taxol and Taxol Analogs through Elaboration of Aromatic C-Ring Precursors. The Journal of Organic Chemistry. 61(22). 7662–7663. 12 indexed citations
13.
Wender, Paul A., Ludger A. Wessjohann, Bernd Peschke, & David B. Rawlins. (1995). The pinene path to taxol: Readily accessible a-ring building blocks based on novel alkyl- and alkenyllithium reagents with internal carbonyl groups. Tetrahedron Letters. 36(40). 7181–7184. 11 indexed citations
14.
Fleming, Steven A., David B. Rawlins, Vicente Sámano, & Morris J. Robins. (1992). Photochemistry of nucleoside transport inhibitor 6-S-benzylated thiopurine ribonucleosides. Implications for a new class of photoaffinity labels. The Journal of Organic Chemistry. 57(22). 5968–5976. 17 indexed citations
15.
Wender, Paul A. & David B. Rawlins. (1992). Toward the synthesis of the taxol C,D, ring system: Photolysis of α-methoxy ketones. Tetrahedron. 48(34). 7033–7048. 31 indexed citations
16.
Wender, Paul A. & David B. Rawlins. (1992). ChemInform Abstract: Toward the Synthesis of the Taxol C,D Ring System: Photolysis of . alpha.‐Methoxy Ketones.. ChemInform. 23(50). 1 indexed citations
17.
Fleming, Steven A., David B. Rawlins, & Morris J. Robins. (1990). Photochemistry of the nucleoside membrane transport inhibitor 6-[(4-nitrobenzyl) thio]-9-(β-D-ribofuranosyl)purine. Tetrahedron Letters. 31(35). 4995–4998. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Takashi Santou Breakdown of academic impact, for papers by Toshiaki Sakamoto Breakdown of academic impact, for papers by Monica Einstein Breakdown of academic impact, for papers by Denise Blum‐Kaelin Breakdown of academic impact, for papers by Dirk Leysen Breakdown of academic impact, for papers by Yoshimitsu Komatsu Breakdown of academic impact, for papers by Delvin R. Knight Breakdown of academic impact, for papers by Changyou Zhou Breakdown of academic impact, for papers by Guiqing Liang Breakdown of academic impact, for papers by George Chiu
Rankless by CCL
2026